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A B ST R AC T 
 
A R T IC LE D A T A 
Imatinib is generally well tolerated, with mild common side effects such 
as nausea and vomiting, diarrhea, muscle cramps, fatigue, skin rash and 
edema; however, pulmonary complications are uncommon. A 73-year-old 
woman undergoing one month treatment with Imatinib for chronic 
myeloid neoplasm associated with eosinophilia was admitted for sudden 
alteration of her performance status, dyspnea at rest and productive 
cough. On clinical examination, the patient was hypoxic (oxygen 
saturation on room air was 87%), and auscultation of her lungs revealed 
diffuse bilateral fine crackles. Computed tomography showed bilateral 
pulmonary interstitial syndrome. Imatinib was discontinued and the 
patient received systemic corticosteroid therapy and oxygen therapy. 
After one month, the symptoms and radiological findings were resolved. 
When Imatinib therapy was resumed, respiratory symptoms reappeared, 
which is why treatment with Imatinib was interrupted. Imatinib-induced 
pneumonitis should take into consideration when patients develop 
respiratory symptoms or abnormal pulmonary radiological features. 
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Tyrosine kinase inhibitors are the main class of drugs 
used for the treatment of chronic myeloid leukemia (CML). 
Imatinib was the first tyrosine kinase inhibitor used and 
significantly increased survival in CML. The mechanism 
consists of inhibition of BCR-ABL1 fusion protein 
(encoded in all cases of Philadelphia chromosome-positive 
CML), but Imatinib also leads to inhibition of other 
tyrosine kinases such as platelet-derived growth factor 
receptor (PDGFR) or tyrosine kinase Kit [1]. The fusion of 
tyrosine kinase genes has been observed to be involved in 
the occurrence of primary eosinophilia cases. The World 
Health Organization recognizes the category of 
myeloid/lymphoid neoplasms associated with eosinophilia 
and rearrangements of PDGFRα, PDGFRβ, FGFR1 genes 
or with PCM1-JAK2 mutation. Imatinib was successfully 
used in patients with myeloid neoplasm associated with 
eosinophilia and FIP1-like1-platelet-derived growth factor 
receptor-alpha (FIP1L1-PDGFRA) mutation. The results 
were confirmed by many studies using daily doses from 
100 mg to 400 mg. Unlike CML, very few cases of 
resistance to Imatinib occurred in patients with FIP1L1-
PDGFRA mutation [2]. Imatinib is considered to be 
relatively well tolerated. The most frequent non-
hematological adverse effects (in more than 10% of the 
patients) caused by its use are edema (60%, particularly 
infraorbital edema), nausea, vomiting, diarrhea, skin 
changes (rash in 35% of the cases at the onset of therapy, 
pruritus, hyper/hypopigmentation, photosensitivity, rarely 
exfoliative dermatitis or Stevens-Johnson syndrome within 
10 days of initiation of therapy), and musculoskeletal pain. 
Between 1 and 10% of patients exhibit neutropenia, 
pancytopenia or mild hepatotoxicity. The greatest number 
of side effects occur during the first two years of treatment, 
and some of these remit even when treatment is continued 
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with the same dose. Very rarely (less than 1% of the cases), 
long-term use of Imatinib may cause cardiotoxicity, 
pulmonary toxicity, secondary malignancy, renal failure or 
opportunistic infection [3].  
Respiratory side effects caused by Imatinib are rare 
(<1.3%); of these, cough, dyspnea and upper respiratory 
tract infections have been reported [4,5]. The development 
of pneumonitis as an adverse effect of treatment with 
Imatinib is extremely rare and has only been described by 
isolated case reports. Symptoms are non-specific and can 
also be found as part of other diseases. 
Imatinib-induced interstitial lung disease (ILD) 
generally develops at about 2 months (range 10-282 days) 
after initiation of treatment, following administration of 
mean Imatinib doses of 400 mg (200 mg-600 mg) [4,6]. 
The literature data emphasize a higher incidence of this 
adverse effect in the case of patients with preexisting lung 
diseases [6].  
We report the first case of ILD in Romania in a patient 
with myeloid neoplasm associated with hypereosinophilia. 
This patient developed acute respiratory failure at about 
one month after initiation of treatment with Imatinib in a 
dose of 100 mg/day. Symptoms and imaging lung changes 
improved following cessation of treatment with tyrosine 
kinase inhibitor and administration of corticosteroids. 
Resumption of Imatinib treatment led to the reappearance 
of respiratory symptoms, which required discontinuation of 
immunosuppressive treatment.  
Case report 
We report the case of a 73-year-old female patient 
who presented to our service for rest dyspnea starting 
about 2 weeks before and worsening over the last 12 
hours, associated with cough with mucous expectoration, 
extreme asthenia, somnolence and dysthymia. She had a 
medical history of essential hypertension grade III, silent 
ischemic heart disease, poorly controlled type 2 insulin-
dependent diabetes mellitus complicated by diabetic 
retinopathy, autoimmune thrombocytopenic purpura 
treated by splenectomy. Two months before, she was 
diagnosed with chronic myeloid leukemia associated with 
eosinophilia with positive FIP1L1-PDGFRA fusion 
kinase, for which Imatinib in a dose of 100 mg/day and 
Allium cepa L extract for the antioxidant and antiplatelet 
effect were initiated one month before [7]. 
On objective examination, the patient had an altered 
general state with a performance index 3, generalized 
pallor with lip cyanosis. Objective chest examination 
showed kyphotic chest, pulmonary sonority, harsh 
vesicular murmur, diffuse bilateral crackles, room air 
arterial blood oxygen saturation (SaO2) = 87%, corrected 
to 95% after oxygen therapy by nasal cannula.  
Initial investigations included chest computed 
tomography (CT), which evidenced in the lung, starting 
with the apex, a bilateral interstitial pattern with reticular 
appearance and in some places with ground-glass 
appearance, alternating with several areas of discrete 
condensation and positive air bronchogram in the upper 
lobes, anteriorly, more obvious to the left; in the middle 
lobes without condensation, radiological changes 
decreased in intensity towards the lung bases (Figure 1). 
 
Figure 1. Chest computer tomography scan showing 
signs of interstitial lung disease (admission) 
Blood tests showed marked inflammatory syndrome 
(leukocytosis with neutrophilia, elevated C-reactive 
protein and erythrocyte sedimentation rate. Infectious 
evaluation was performed by sputum examination – 
negative, blood cultures – negative, CMV IgM – negative, 
determination of Aspergillus galactomannan antigen titer 
in serum – negative, in sputum – positive (Table 1). 
Table 1. Laboratory results on admission 
Biological parameter Value Normal value 
White blood cells 15,500 4-10*103/µl 
Neutrophils 11,000 1.5-7*103/µ 
Eosinophils 10 < 350/µl 
Hemoglobin 11.9 11-16 g/dl 
Platelets 517,000 150-450*103/µl 
Erythrocyte 
sedimentation rate  
30 1-10 mm/h 
C-reactive protein 65 < 10 mg/l 
Sputum test Microbial flora belonging to the 
oropharyngeal microbiocenosis; no fungi 
Blood culture negative 




0.08 < 0.5 
Sputum Aspergillus 
galactomannan antigen  
5.27 < 0.5 
BNP2 46.5 < 100 pg/ml 
FIP1L1-PDGFRA3 Negative Negative 
1CMV IgM – cytomegalovirus immunoglobulin M antibodies; 2BNP – 
brain natriuretic peptide; 3FIP1L1-PDGFRA – FIP1-like1-platelet-
derived growth factor receptor-alpha;  
Eosinophil count decreased under treatment both at the 
periphery and in the hematogenous bone marrow (at the time 
of the diagnosis of hypereosinophilic syndrome (HES): 
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complete blood count 26% eosinophils; medullogram 30% 
eosinophils, predominantly mature cells). 
The cardiac etiology of dyspnea was excluded by 
transthoracic echocardiography which evidenced a left 
ventricular ejection fraction higher than 50%, and brain 
natriuretic peptide dosage excluded cardiac disease 
(Figure 2). 
 
Figure 2. Differential diagnosis (1BNP – brain natriuretic 
peptide; 2LVEF – left ventricular ejection fraction; 3CBC 
– complete blood count; 4HES – hypereosinophilic 
syndrome; 5FIP1L1-PDGFRA – FIP1-like1-platelet-
derived growth factor receptor alpha) 
Sputum examination and blood cultures were 
performed in order to exclude an infectious etiology of 
pneumonitis (bronchopneumonia, atypical pneumonia, 
etc.). However, Aspergillus galactomannan antigen was 
detected in sputum, serum Aspergillus galactomannan 
being negative.  
Alveolar hemorrhage was excluded both by clinical 
examination – the patient did not present hemoptysis, and 
by biological examination – the patient did not have 
anemia (hemoglobin = 11.9 g/dl, within normal limits). 
The suspicion of new tumor proliferation was raised, 
but this was denied by the blood picture within normal 
limits; relapse of myeloid neoplasm with eosinophilia was 
refuted by negative FIP1L1-PDGFRA fusion kinase.  
Given that the patient was diagnosed with myeloid 
neoplasm associated with eosinophilia two months before, 
for which she received 1 month treatment with Imatinib, 
the suspicion of Imatinib-induced toxicity was raised. 
Imatinib treatment was discontinued, systemic and 
inhaled corticotherapy was administered (oral Prednisone 
40 mg with the progressive reduction of doses up to 10 
mg/day after 2 weeks), as well as continuous oxygen 
therapy and oral antifungal drugs (oral Posaconazole 300 
mg) for the suspicion of pulmonary aspergillosis. The 
patient was discharged in an improved condition, being 
dependent on oxygen at home, with the indication of 
continuing corticoid (oral Prednisone 10 mg/day) and 
antifungal treatment (oral Posaconazole 300 mg), as well 
as the indication of discontinuing Imatinib treatment. 
One month later, the patient was reevaluated by chest 
CT, which showed complete resorption of interstitial 
lesions and preexisting infiltrates (Figure 3). 
 
Figure 3. Chest computer tomography scan – one month 
after Imatinib discontinuation 
Considering the complete resorption of lesions, the 
problem of resuming Imatinib therapy to treat the HES 
was posed. Ten days after resumption of treatment with 
Imatinib 100 mg/day, the patient exhibited progressive 
exertional dyspnea and hypoxemia (SaO2 on room air = 
90%), which is why she was reassessed by chest CT that 
evidenced the reappearance of interstitial lesions. Imatinib 
treatment was stopped once again and administration of 
corticotherapy (Prednisone 15 mg/day) was continued, 
treatment under which the pulmonary lesions remitted in 
2 weeks.  
Discussions 
Adverse drug reactions due to antineoplastic agents 
are a common form of iatrogenic injury and the lungs are 
frequently involved [8-10]. About 10-20% of all patients 
treated with an antineoplastic agent have some form of 
lung toxicity, although the incidence varies depending on 
the specific agent, dose and other factors [11-15].  
Imatinib is generally well tolerated with mild common 
side effects such as nausea and vomiting, diarrhea, muscle 
cramps, fatigue, skin rash and edema; however, 
pulmonary complications are uncommon [5]. Most of the 
lung complications reported during Imatinib therapy have 
been related to fluid retention. Nevertheless, peripheral 
and periorbital edema are far more frequent 
manifestations of fluid retention than are pleural or 
pericardial effusions and pulmonary edema [16-18]. 
Furthermore, ILD is a rare entity [6,19-25]. 
Ohnishi et al. analyzed the side effects associated with 
Imatinib therapy in 5000 patients with CML and 500 
patients with gastrointestinal stromal tumor [26-32]. Only 
27 patients appeared to have developed ILD. The median 
period until ILD developed was 49 days (range: 10–282 
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days) and the median daily dose of Imatinib was 400 mg 
(range: 200–600 mg) at the time when ILD was 
diagnosed. Lung toxicity has been reported with doses as 
low as 100 mg per day [27, 33-38]. However, there was 
no clear correlation between the development of ILD and 
either the dose or duration of Imatinib therapy, but the 
incidence of the disease seemed higher in patients who 
had preexisting pulmonary diseases. Preexisting lung 
disease was present in more than 40% of patients with 
ILD [38]. In the case of our patient, it took one month for 
IDL to occur and the dosage of Imatinib was only 100 
mg/day. Our patient had no previous lung disease. 
ILD is thought to be the result of an immune complex-
mediated reaction involving T cells and cytokines. If 
allowed to progress, the inflammation can extend to the 
pulmonary interstitium and its capillaries, leading to 
pneumosclerosis, alveolar deformation and disturbances 
of lung diffusion capacity [31]. It is unclear whether the 
mechanism is a drug hypersensitivity phenomenon or a 
pharmacological effect of tyrosine kinase inhibition. The 
diffuse ground-glass opacities seen on CT scan and 
lymphocytic infiltrate showed by transbronchial biopsy, 
as well as resolution with drug cessation and 
corticosteroid therapy suggest a hypersensitivity 
phenomenon, as has been reported in the literature 
[19,23]. Alternatively, interstitial pneumonitis could 
probably be a pharmacological effect. Imatinib aggravates 
interstitial pneumonitis by inhibiting PDGF tyrosine 
kinase, which leads to acute lung injury [39, 40]. 
Diagnosis is based on history, radiological findings 
and pathology results. It may be challenging as signs and 
symptoms are often non-specific. Malaise, low-grade 
fever, dyspnea and cough seem to prevail [41]. Chest 
radiographs show different patterns such as interstitial 
pneumonitis, cryptogenic-organizing pneumonia, nodular 
or peribronchovascular lesions and diffuse alveolar 
damage [38]. Pathology features also vary and may 
include diffuse alveolar damage, non-specific interstitial 
pneumonia, bronchiolitis obliterans organizing 
pneumonia, eosinophilic pneumonia and pulmonary 
hemorrhage [42]. 
Management of drug-induced pneumonitis involves 
immediate discontinuation of the triggering agent. 
Although the syndrome may resolve with drug 
discontinuation alone [21,27,36], most cases require 
glucocorticoid therapy for resolution [4,20,29,37]. Only 
one fatality has been reported [20].  
A resumption of Imatinib therapy may be considered 
when the patient has displayed improvement both 
clinically and radiologically [30,43]. Serial imaging may 
be required to ensure resolution. 
Resumption does not always prompt a recurrence of 
lung injury [38]. In the Japanese series described above, 
Imatinib was readministered to 11 patients after ILD 
improved; four had a recurrence of lung toxicity. 
However, in general, resumption is not recommended 
unless other therapeutic options are not available. 
It was confirmed that our patient had drug-induced 
interstitial pneumonitis since her symptoms and 
radiological findings improved after Imatinib withdrawal 
and steroid therapy initiation, and even more since 
symptoms and radiological findings reoccurred after 
Imatinib therapy resumption. 
To our knowledge, our report represents the first 
published case of IDL in a patient with CML in Eastern 
Europe and the second case worldwide of pneumonitis 
induced by Imatinib at a low dose of 100 mg/day. 
Highlights 
Respiratory side effects caused by Imatinib are rare 
(<1.3%); of these, cough, dyspnea and upper respiratory 
tract infections have been reported. 
The development of pneumonitis as an adverse effect 
of treatment with Imatinib is extremely rare and has only 
been described by isolated case reports. Symptoms are 
non-specific and can also be found as part of other 
diseases. 
Conclusions 
Drug-induced pneumonitis is a rare complication of 
Imatinib treatment. Initial diagnosis may be challenging 
due to non-specific signs and symptoms and may be 
mistaken for more common infectious etiologies. This 
report widens the spectrum of Imatinib-induced 
pneumonitis that clinicians should take into consideration 
when patients undergoing Imatinib treatment develop 
respiratory symptoms or abnormal pulmonary 
radiological features. 
Informed consent: The patient has provided informed 
consent for publication of the case. 
Funding: This research received no external funding. 
Conflicts of Interest: The authors declare no conflict 
of interest. 
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